>精神科/うつ病における世界の薬理遺伝学検査市場、タイプ別（不安、うつ病、気分障害、双極性障害、摂食障害、精神病性障害）、製品別（消耗品、器具、ソフトウェアおよびサービス）、検査タイプ別（全ゲノム配列解析および染色体アレイベースの検査）、遺伝子タイプ別（CYP2C19、CYP2C9およびVKORC1、CYP2D6、HLA-B、HTR2A/C、HLA-A、CYP3A4、SLC6A4、MTHFR、COMT、その他）、患者タイプ別（成人、高齢者、小児）、エンドユーザー別（病院および診療所、診断研究所、学術研究機関、その他）、流通チャネル別（直接入札、第三者流通、病院薬局、その他） - 2031年までの業界動向および予測。
精神医学/うつ病における薬理遺伝学検査の市場分析と洞察
精神疾患やうつ病に苦しむ患者数の増加が、市場の成長を牽引すると予想されています。個別化医療や精密医療の需要の高まりが、市場の成長を後押ししています。熟練した医療およびゲノム専門家の不足と強力な臨床的証拠の欠如が、市場の成長を妨げる可能性があります。しかし、技術の進歩の高まりが、市場の成長の機会として機能することが期待されています。
データブリッジマーケットリサーチは、精神科/うつ病における世界の薬物遺伝子検査市場は、2023年の12億2,000万米ドルから2031年には26億6,000万米ドルに達し、2024年から2031年の予測期間に10.4%のCAGRで成長すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2024年から2031年 |
|
基準年 |
2023 |
|
歴史的な年 |
2022 (2016～2021年にカスタマイズ可能) |
|
定量単位 |
売上高（10億米ドル）と販売数量（個数） |
|
対象セグメント |
タイプ (不安、うつ病、気分障害、双極性障害、摂食障害、精神病)、製品 (消耗品、機器、ソフトウェアおよびサービス)、検査タイプ (全ゲノム配列解析および染色体アレイ ベースの検査)、遺伝子タイプ (CYP2C19、CYP2C9 および VKORC1、CYP2D6、HLA-B、HTR2A/C、HLA-A、CYP3A4、SLC6A4、MTHFR、COMT、その他)、患者タイプ (成人、高齢者、小児)、エンド ユーザー (病院および診療所、診断研究所、学術研究機関、その他)、流通チャネル (直接入札、第三者流通、病院薬局、その他) |
|
対象国 |
米国、カナダ、メキシコ、ドイツ、英国、フランス、イタリア、オランダ、スペイン、ロシア、スイス、トルコ、ポーランド、ノルウェー、ハンガリー、オーストリア、アイルランド、リトアニア、その他のヨーロッパ諸国、中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、インドネシア、マレーシア、フィリピン、ベトナム、その他のアジア太平洋諸国、ブラジル、アルゼンチン、ペルー、その他の南米諸国、サウジアラビア、UAE、イスラエル、南アフリカ、エジプト、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., Sonic Healthcare Limited, QIAGEN, AB-BIOTICS S.A., BiogeniQ Inc., Castle Bioscience Inc., Coriell Life Sciences, Dynamic DNA Laboratories, Eurofins Scientific, Genelex, Genewiz, Genomind Inc., GenXys, HealthSpek, HudsonAlpha, MD Labs, ONEOME LLC, and PacBio among others |
Market Definition
Pharmacogenetics testing studies the interaction between the drug and the gene response of a person and searches for the gene variation that is responsible for influencing the drug effect. The test is gaining high demand as many researchers and scientists identified the unique interaction between drugs and individual genes and provides valuable insights that subsequently be used to develop customized or personalized medication.
Pharmacogenetics Testing in Psychiatry/Depression Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Number of Population Suffering from Depressive Disorder
Depression is a prevalent condition globally that varies from normal mood changes. Depression can become a serious health condition of mild to extreme severity, affecting the person to suffer greatly, and can lead to suicide in the worst cases. While over 45 antidepressants are available, suboptimal response poses difficulty and is considered to be a result of genetic variation.
With the rising prevalence of depression, the demand for pharmacogenetics testing is also increasing as it studies the effect of genetic variants to provide tailored treatment, which is driving the market growth.
- Growing Biotechnology Sector along with Rising Healthcare Expenditure
People are becoming more aware of their health and also there is alertness for preventive healthcare. Emphasis on healthcare is gaining popularity. Awareness of disease and symptoms is essential for screening and early detection of diseases due to advanced technology available in the healthcare system such as advanced testing which helps the healthcare providers and leads to higher survival rates.
The growing biotechnology sector, coupled with rising healthcare expenditure globally, is anticipated to drive the pharmacogenetics testing market in the fields of psychiatry and depression. There is an increased focus on personalized medicine, including pharmacogenetics testing, as biotechnology companies develop innovative testing methods and technologies. This, combined with the rising healthcare expenditure, indicates a growing investment in advanced healthcare solutions that could improve patient outcomes and reduce overall healthcare costs, which is boosting the market growth.
Opportunity
- Advancements in Genetic Testing
The field of healthcare is experiencing rapid technological advancements, particularly in the development of new and sophisticated methods to promote pharmacogenetics testing. These innovative tests utilize advanced genetic testing methods to provide precise results, enabling healthcare providers to tailor treatment regimens more effectively. This advancement presents a significant opportunity for the global pharmacogenetics testing market in psychiatry and depression. As these cutting-edge technologies become more accessible and refined, they have the potential to revolutionize personalized medicine, offering patients more targeted and effective treatments for mental health conditions.
These tests play a crucial role in establishing a meaningful connection between a drug and an individual's genetic profile. This personalized approach aids healthcare providers in selecting the most suitable medications for patients suffering from major depressive disorders and other psychiatric conditions. By leveraging advancements in genetic testing, pharmacogenetics testing can significantly enhance treatment outcomes and improve patient care in psychiatry and depression, which is expected to create an opportunity for market growth.
Restraints/Challenges
- Insufficient Clinical Validation
With advancements in medical sciences, new testing methods are being increasingly developed to come up with potent drugs that are efficient in treating major depressive disorders. The antidepressants and the antipsychotics used in the treatments can be ineffective. They can help in suggesting the drugs that can be used to treat the disease as per individual patient needs.
Even though having such an advantage, the tests lack a strong clinical basis to completely rely on them. Although studies conducted on small populations have shown promising results, the efficacy of the tests has no evidence on the larger population.
The pharmacogenetics testing in psychiatry does not assess for non-compliance in treatment outcomes. As a result, when the rate of non-adherence increases in the population being considered, the power of the statistics lowers leading to a lack of evidence to prove the efficiency of the tests.
The lack of basis to entirely depend on these tests is a major drawback in the market. The patients would prefer to stick to traditional methods of testing and thus, it is hindering the market growth.
- Rising Concern Regarding Data Privacy and Security
Pharmacogenetic testing, which analyzes how an individual's genetic makeup influences their response to medications, raises significant concerns about data privacy and security, particularly in the context of global data sharing and storage. Genetic information is inherently personal and can reveal sensitive details about an individual health, including predispositions to certain diseases and responses to specific drugs. As such, there is a heightened risk of this information being misused or improperly accessed if not adequately protected.
A major concern is the risk of genetic discrimination, where individuals could experience negative outcomes in employment or insurance due to their genetic information. Data breaches are another significant risk, particularly as genetic information is increasingly shared across borders for research or clinical purposes. The transfer of data between jurisdictions with differing privacy regulations can further complicate efforts to ensure data security.
Data privacy and security stand out as significant challenges for the global implementation of pharmacogenetic testing in the psychiatry depression market due to the sensitive nature of genetic information, there is a potential risk of misuse or unauthorized access of patients data which they have provided. The sensitive nature of the data can give rise to several issues, which are expected to challenge the market growth.
Recent Developments
- In February 2024, Myriad Genetics, Inc., a pioneer in genetic testing and precision medicine, has acquired select assets from Intermountain Health's Precision Genomics (IPG) laboratory. This includes the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah. This acquisition allows Myriad to enhance its tumor profiling offerings and expand its oncology portfolio, which includes hereditary cancer and companion diagnostic testing options
- In February 2024, QIAGEN announced that it has been recognized for its sustainability efforts by My Green Lab, a non-profit organization focused on promoting sustainability in scientific research. This will enhance QIAGEN's reputation for sustainability, potentially attracting environmentally conscious customers and partners
- In November 2023, QIAGEN and DNA Labs International collaborated to solve two decades-old cold cases using QIAGEN's ForenSeq Kintelligence System for forensic genetic genealogy, in conjunction with the GEDmatch PRO database. This highlights the effectiveness and increasing adoption of this approach to human identification. This will result in the effectiveness of QIAGEN's forensic genetic genealogy solutions, potentially boosting their adoption and sales in the forensic market
- In June 2022, Castle Biosciences, Inc, a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. This acquisition would enable to potentially develop a mental health franchise, starting with a test that currently receives Medicare reimbursement for depression
- In May 2022, Coriell Life Sciences won Second MedTech Breakthrough Award for Genomics Innovation which leads the way in unlocking the power of pharmacogenomics to improve healthcare. the organization’s Corigen Medication Safety Program has been named “Best Overall Genomics Solution” in the 2022 MedTech Breakthrough Awards. The award will give the testing more credibility among the users
Global Pharmacogenetics Testing in Psychiatry/Depression Market Scope
The global pharmacogenetics testing in psychiatry/depression market is segmented into seven notable segments based on type, product, test type, gene type, patient type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Anxiety
- Depression
- Mood Disorders
- Bipolar Disorders
- Eating Disorders
- Psychotic Disorders
On the basis of type, the global pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, depression, mood disorders, bipolar disorders, eating disorders, and psychotic disorders.
Product
- Consumables
- Instruments
- Software and Services
On the basis of product, the global pharmacogenetics testing in psychiatry/depression market is segmented into consumables, instruments, and software and services.
Test Type
- Whole Genome Sequencing
- Chromosomal Array Based Tests
On the basis of test type, the global pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing and chromosomal array based tests.
Gene Type
- CYP2C19
- CYP2C9 and VKORC1
- CYP2D6
- HLA-B
- HTR2A/C
- HLA-A
- CYP3A4
- SLC6A4
- MTHFR
- COMT
- Others
On the basis of gene type, the global pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others.
Patient Type
- Adult
- Geriatric
- Child
On the basis of patient type, the global pharmacogenetics testing in psychiatry/depression market is segmented into adult, geriatric, and child.
End User
- Hospital and Clinics
- Diagnostics Laboratories
- Academic and Research Institutes
- Others
On the basis of end user, the global pharmacogenetics testing in psychiatry/depression market is segmented into hospital and clinics, diagnostics laboratories, academic and research institutes, and others.
Distribution Channel
- Direct Tender
- Third Party Distribution
- Hospital Pharmacy
- Others
On the basis of distribution channel, the global pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third party distribution, hospital pharmacy, and others.
Global Pharmacogenetics Testing in Psychiatry/Depression Market Regional Analysis/Insights
The global pharmacogenetics testing in psychiatry/depression market is segmented into seven notable segments based on type, product, test type, gene type, patient type, end user, and distribution channel.
The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Turkey, Poland, Norway, Hungary, Austria, Ireland, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, and rest of Middle East and Africa.
North America is expected to dominate the global pharmacogenetics testing in psychiatry/depression market as increasing number of population suffering from depressive disorder in the region. The U.S. is expected to dominate the North America region because robust initiatives taken by manufacturers due to genetic variability. China is expected to dominate the Asia-Pacific region due to the growing biotechnology sector along with rising healthcare expenditure. Germany is expected to dominate the Europe region due to increasing interest for personalized and precision medication.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Global Pharmacogenetics Testing in Psychiatry/Depression Market Competitive Landscape and Share Analysis
The global pharmacogenetics testing in psychiatry/depression market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the global pharmacogenetics testing in psychiatry/depression market.
この市場で活動している主要企業としては、Thermo Fisher Scientific Inc.、Illumina Inc.、Myriad Genetics Inc.、Sonic Healthcare Limited、QIAGEN、AB-BIOTICS SA、BiogeniQ Inc.、Castle Bioscience Inc.、Coriell Life Sciences、Dynamic DNA Laboratories、Eurofins Scientific、Genelex、Genewiz、Genomind Inc.、GenXys、HealthSpek、HudsonAlpha、MD Labs、ONEOME LLC、PacBio などが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
- introduction
- OBJECTIVES OF THE STUDY
- MARKET DEFINITION
- OVERVIEW of Global pharmacogenetic testing in psychiatry/depression market
- LIMITATIONs
- MARKETS COVERED
- MARKET SEGMENTATION
- MARKETS COVERED
- geographical scope
- years considered for the study
- currency and pricing
- DBMR TRIPOD DATA VALIDATION MODEL
- MULTIVARIATE MODELLING
- type LIFELINE CURVE
- primary interviews with key opinion leaders
- DBMR MARKET POSITION GRID
- market application coverage grid
- vendor share analysis
- secondary sourcEs
- assumptions
- EXECUTIVE SUMMARY
- premium insights
- REGULATIONS: GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
- UNITED STATES
- ROLE OF FDA
- ROLE OF CDC AND HCFA
- EUROPEAN UNION
- FRANCE
- AUSTRALIA
- SOUTH KOREA
- market overview
- drivers
- RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
- INITIATIVES TAKEN BY MANUFACTURERS
- GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
- INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
- GROWING MEDICAL TOURISM
- RESTRAINTS
- LACK OF STRONG CLINICAL EVIDENCE
- HIGH COST
- LACK OF REIMBURSEMENT
- OPPORTUNITIES
- TECHNOLOGICAL ADVANCEMENTS
- EMERGENCE OF NEW PLAYERS
- Untapped market
- CHALLENGES
- STRINGENT GOVERNMENT REGULATION
- SHORTAGE OF SKILLED PERSONNEL
- COVID-19 IMPACT ON GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
- IMPACT ON PRICE
- IMPACT ON DEMAND
- IMPACT ON SUPPLY
- KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
- CONCLUSION:
- GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE
- overview
- WHOLE GENOME SEQUENCING
- array-based TESTS
- GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES
- overview
- cyp2c19
- CYP2C9 and VKORC1
- cyp2d6
- HLA-B
- htr2a/c
- HLA-A
- cyp3A4
- slc6a4
- MTHFR
- COMT
- others
- GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE
- overview
- PRESCRIPTION DRUGS
- Over-the-counter medications
- RECREATIONAL DRUGS
- VITAMINS/NUTRACEUTICals
- GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE
- overview
- SALIVA
- BLOOD
- GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY application
- overview
- DRUG DEVELOPMENT
- CLINICAL PRACTICE
- GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER
- overview
- pharmaceutical and biotechnology companies
- HEALTHCARE PROVIDERS
- research centers and academic institues
- others
- GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL
- overview
- RETAIL PHARMACIES
- HOSPITAL PHARMACIES
- MAIL-ORDER PHARMACIES
- DIRECt-to-customer services
- GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, by Geography
- overview
- north america
- u.s.
- canada
- mexico
- europe
- u.k.
- germany
- france
- italy
- spain
- netherlands
- belgium
- russia
- switzerland
- turkey
- rest of europe
- Asia-Pacific
- JAPAN
- cHINA
- SOUTH KOREA
- INDIA
- AUSTRALIA
- SINGAPORE
- THAILAND
- MALAYSIA
- indonesia
- philipPines
- rest of asia-pacific
- south america
- BRAZIL
- argentina
- rest of south america
- middle east & africa
- south africa
- saudi arabia
- uae
- israel
- egypt
- rest of middle east & africa
- Global Pharmacogenetic Testing in psychiatry/depression Market: COMPANY landscape
- company share analysis: Global
- company share analysis: North America
- company share analysis: Europe
- company share analysis: Asia-Pacific
- swot analysis
- company profile
- MYRIAD GENETICS, INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- Company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- THERMO FISHER SCIENTIFIC INC.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- Company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- STADA ARZNEIMITTEL AG
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- Company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- sonic healthcare
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- Company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- Illumina, Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- Company share analysis
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- AB-Biotics, S.A.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- 6.3 PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- ALTHEADX
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- biogeniq inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- Color
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- cnsdose
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- CORIELL LIFE SCIENCES
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- Dynamic DNA Laboratories
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- GENELEX
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- genomind, inc.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- genxys
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- HEALTHSPEK
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- HudsonAlpha Health Alliance (A Division of HudsonAlpha)
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- luminex corporation
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- MILLENNIUM HEALTH
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- mydna life australia pty ltd.
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- oneome
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- OMECARE
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENT
- PerkinElmer Inc.
- COMPANY SNAPSHOT
- REVENUE ANALYSIS
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- R-Biopharm AG
- COMPANY SNAPSHOT
- PRODUCT PORTFOLIO
- RECENT DEVELOPMENTS
- questionnaire
- related reports
表のリスト
TABLE 1 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD Million)
TABLE 2 Global Whole Genome Sequencing in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 3 Global Array-Based Tests in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 4 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD Million)
TABLE 5 Global CYP2C19 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 6 Global CYP2C9 AND VKORC1 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 7 Global CYP2D6 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 8 Global HLA-B in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 9 Global HTR2A/C in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 10 Global HLA-A in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 11 Global CYP3A4 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 12 Global SLC6A4 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 13 Global MTHFR in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 14 Global COMT in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 15 Global Others in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD Million)
TABLE 17 Global PRESCRIPTION DRUGS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 18 Global OVER-THE-COUNTER MEDICATIONS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 19 Global RECREATIONAL DRUGS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 20 Global VITAMINS/NUTRACEUTICALS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD Million)
TABLE 22 Global Saliva in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 23 Global blood in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD Million)
TABLE 25 Global Drug Development in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 26 Global Clinical Practice in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD Million)
TABLE 28 Global Pharmaceutical & Biotechnology Companies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 29 Global Healthcare Providers in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 30 Global Research Centres And Academic Institutes in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 31 Global Others in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD Million)
TABLE 33 Global Retail Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 34 Global Hospital Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 35 Global Mail-Order Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million))
TABLE 36 Global Direct-To-Customer Services in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)
TABLE 37 Global Pharmacogenetic Testing in psychiatry/depression Market , By Region, 2021-2028 (USD Million)
TABLE 38 north america pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)
TABLE 39 north america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 40 north america pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 41 north america pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 42 north america pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 43 north america pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 44 north america pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 45 north america pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 46 u.s. pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 47 u.s. pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 48 u.s. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 49 u.s. pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 50 u.s. pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 51 u.s. pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 52 u.s. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 53 canada pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 54 canada pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 55 canada pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 56 canada pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 57 canada pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 58 canada pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 59 canada pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 60 mexico pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 61 mexico pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 62 mexico pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 63 mexico pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 64 mexico pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 65 mexico pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 66 mexico pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 67 europe pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)
TABLE 68 europe pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 69 europe pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 70 europe pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 71 europe pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 72 europe pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 73 europe pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 74 europe pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 75 u.k. pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 76 u.k. pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 77 u.k. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 78 u.k. pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 79 u.k. pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 80 u.k. pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 81 u.k. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 82 germany pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 83 germany pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 84 germany pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 85 germany pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 86 germany pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 87 germany pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 88 germany pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 89 france pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 90 france pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 91 france pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 92 france pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 93 france pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 94 france pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 95 france pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 96 italy pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 97 italy pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 98 italy pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 99 italy pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 100 italy pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 101 italy pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 102 italy pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 103 spain pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 104 spain pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 105 spain pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 106 spain pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 107 spain pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 108 spain pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 109 spain pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 110 netherlands pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 111 netherlands pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 112 netherlands pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 113 netherlands pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 114 netherlands pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 115 netherlands pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 116 netherlands pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 117 belgium pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 118 belgium pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 119 belgium pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 120 belgium pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 121 belgium pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 122 belgium pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 123 belgium pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 124 russia pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 125 russia pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 126 russia pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 127 russia pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 128 russia pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 129 russia pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 130 russia pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 131 switzerland pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 132 switzerland pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 133 switzerland pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 134 switzerland pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 135 switzerland pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 136 switzerland pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 137 switzerland pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 138 turkey pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 139 turkey pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 140 turkey pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 141 turkey pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 142 turkey pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 143 turkey pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 144 turkey pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 145 rest of europe pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 146 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 147 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 148 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 149 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 150 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 151 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 152 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 153 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 154 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 155 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 156 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 157 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 158 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 159 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 160 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 161 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 162 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 163 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 164 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 165 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 166 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 167 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 168 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 169 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 170 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 171 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 172 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 173 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 174 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 175 India PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 176 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 177 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 178 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 179 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 180 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 181 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 182 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 183 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 184 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 185 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 186 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 187 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 188 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 189 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 190 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 191 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 192 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 193 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 194 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 195 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 196 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 197 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 198 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 199 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 200 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 201 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 202 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 203 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 204 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 205 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 206 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 207 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 208 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 209 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 210 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 211 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 212 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 213 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 214 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 215 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 216 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 217 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 218 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)
TABLE 219 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)
TABLE 220 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)
TABLE 221 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)
TABLE 222 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)
TABLE 223 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)
TABLE 224 Rest of Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)
TABLE 225 south america pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)
TABLE 226 south america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 227 south america pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 228 south america pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 229 south america pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 230 south america pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 231 south america pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 232 south america pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 233 brazil pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 234 brazil pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 235 brazil pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 236 brazil pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 237 brazil pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 238 brazil pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 239 brazil pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 240 argentina pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 241 argentina pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 242 argentina harmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 243 argentina pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 244 argentina pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 245 argentina pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 246 argentina pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 247 rest of south america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 248 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)
TABLE 249 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 250 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 251 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 252 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 253 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 254 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 255 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 256 south africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 257 south africa pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 258 south africa pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 259 south africa pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 260 south africa pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 261 south africa pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 262 south africa pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 263 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 264 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 265 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 266 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 267 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 268 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 269 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 270 uae pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 271 uae pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 272 uae pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 273 uae pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 274 uae pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 275 uae pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 276 uae pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 277 israel pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 278 israel pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 279 israel pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 280 israel pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 281 israel pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 282 israel pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 283 israel pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 284 egypt pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
TABLE 285 egypt pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)
TABLE 286 egypt pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)
TABLE 287 egypt pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)
TABLE 288 EGYPT pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)
TABLE 289 egypt pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)
TABLE 290 egypt pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)
TABLE 291 rest of middle east & africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)
図表一覧
FIGURE 1 Global PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION market: segmentation
FIGURE 2 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: data triangulation
FIGURE 3 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DROC ANALYSIS
FIGURE 4 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: global vs REGIONAL MARKET ANALYSIS
FIGURE 5 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: COMPANY RESEARCH ANALYSIS
FIGURE 6 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: INTERVIEW DEMOGRAPHICS
FIGURE 7 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL pharmacogenetic testing in psychiatry/depression MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 Global pharmacogenetic testing in psychiatry/depression market: vendor share analysis
FIGURE 10 Global pharmacogenetic testing in psychiatry/depression market: SEGMENTATION
FIGURE 11 initiatives taken by manufacturers is expected to drive THE Global pharmacogenetic testing in psychiatry/depression market IN THE FORECAST PERIOD of 2021 to 2028
FIGURE 12 whole genome sequencing segment is expected to account for the largest share of the Global pharmacogenetic testing in psychiatry/depression market in 2021 & 2028
FIGURE 13 NORTH AMERICA is expected to DOMINATE the gLOBAL pharmacogenetic testing in psychiatry/depression market and ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 asia-pacific is the fastest growing market for pharmacogenetic testing in psychiatry/depression manufacturers in the forecast period of 2021 to 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
FIGURE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028
FIGURE 17 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 18 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 19 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028
FIGURE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)
FIGURE 22 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)
FIGURE 23 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE
FIGURE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028
FIGURE 25 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)
FIGURE 26 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 28 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028
FIGURE 29 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)
FIGURE 30 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
FIGURE 31 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE
FIGURE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028
FIGURE 33 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 34 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 35 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 36 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028
FIGURE 37 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 38 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)
FIGURE 39 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028
FIGURE 41 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 42 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 43 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
FIGURE 45 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2020)
FIGURE 46 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2021 & 2028)
FIGURE 47 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2020 & 2028)
FIGURE 48 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)
FIGURE 49 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
FIGURE 50 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
FIGURE 51 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 52 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 53 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)
FIGURE 54 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
FIGURE 55 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
FIGURE 56 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 57 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 58 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)
FIGURE 59 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
FIGURE 60 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
FIGURE 61 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 62 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 63 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)
FIGURE 64 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
FIGURE 65 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
FIGURE 66 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 67 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 68 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)
FIGURE 69 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
FIGURE 70 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
FIGURE 71 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
FIGURE 72 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
FIGURE 73 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)
FIGURE 74 Global Pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)
FIGURE 75 North America pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)
FIGURE 76 Europe pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)
FIGURE 77 Asia-Pacific pharmacogenetic testing in psychiatry/DEPRESSION MARKET: company share 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
